BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1496 related articles for article (PubMed ID: 15667959)

  • 1. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
    Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
    Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.